| 摘要 |
A first aspect of the invention relates to a combination comprising docetaxel, or a derivative or prodrug thereof, and a CDK inhibitor. A second aspect of the invention relates to a pharmaceutical product comprising docetaxel, or a derivative or prodrug thereof, and a CDK inhibitor as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method of treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering a docetaxel, or a derivative or prodrug thereof, and a CDK inhibitor to a subject.
|
